[Secondary tumors of the pancreas - from origins to therapeutic options]

The pancreas is an unusual site for the development of metastases. Metastatic tumors affecting pancreas can be isolated or diffuse, and regarding the time of appearance they can be synchronous or metachronous. According to their origin, the prognosis of different secondary pancreatic tumors varies. The purpose of the literature review is to provide a clearer picture of metastases in the pancreas and their therapeutic potential. We conducted a retrospective review of the literature between 2014 and 2023 using the PubMed database. Using the data obtained during our search, we classified secondary pancreatic tumors based on their incidence, site of primary malignant tumor, clinical symptoms, diagnosis, mechanisms of development and treatment principles. Secondary tumors of the pancreas are rare, accounting for 2–5% of malignant pancreatic tumors. Clear cell renal cell carcinoma is the most common cause of pancreas metastasis. Pancreatic metastases are difficult to diagnose being often asymptomatic, and they can be confused with primary tumors of the pancreas. Histological and immunohistochemical examinations are necessary. In the development of secondary pancreatic tumors, the systemic-hematogenous metastasis mechanism is the accepted one. Surgical treatment prolongs survival, and the use of systemic, molecular targeted therapy has recently proven to be effective. Orv Hetil. 2025; 166(15): 563–568.